

Functional BAFF (human) Antibody, mAb (blocking)
Catalog # ADP0010**Specification**

Functional BAFF (human) Antibody, mAb (blocking) - Product Information

| | |
|------------------|--|
| Application | IP |
| Reactivity | Human |
| Host | Purified From Concentrated Hybridoma Tissue Culture Supernatant. |
| Clonality | Monoclonal |
| Isotype | Rat IgG2a |
| Gene Source | Human |
| Application Note | ,Functional Application, Inhibition of human BAFF binding,IP(1:200) |
| Dilution | IP~~N/A |

Functional BAFF (human) Antibody, mAb (blocking) - Additional Information**Other Names**

BLyS; TALL-1; CD257; B Cell Activating Factor; TNFSF13B

Target/Specificity

Recognizes human BAFF.

Format

Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.

Reconstitution & Storage

Stable for at least 1 year after receipt when stored at -20°C.

Precautions

Functional BAFF (human) Antibody, mAb (blocking) is for research use only and not for use in diagnostic or therapeutic procedures.

Functional BAFF (human) Antibody, mAb (blocking) - Protein Information**Functional BAFF (human) Antibody, mAb (blocking) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)

- [Flow Cytometry](#)
- [Cell Culture](#)

Functional BAFF (human) Antibody, mAb (blocking) - Images**Functional BAFF (human) Antibody, mAb (blocking) - Background**

BAFF is a master regulator of peripheral B cell survival, and together with IL-6, promotes Ig class-switching and plasma cell differentiation. BAFF co-stimulates activated T cells. Increased levels of soluble BAFF have been detected in the serum of patients with various autoimmune diseases, such as Sjögren's syndrome, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (SLE). Furthermore, BAFF is found in inflammatory sites in which there is lymphoid neogenesis. BAFF levels are elevated in patients with multiple myeloma and B cell chronic lymphoid leukemia (B-CCL).